Protgen Ltd   Report issue

For profit Phase 2 Phase 3
Founded: Beijing China (2004)
Status: No NME R&D (2004)

Organization Overview

First Clinical Trial
2009
NCT01223924
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Protgen Ltd

Active Ingredients

Drugs in Phase 3 Trials (1)

albumin (Human) (Plasbumin) (3 trials)

Drugs in Phase 2 Trials (3)

carboplatin (paraplatin) (1 trial)

endostatin (endostar) (5 trials)

paclitaxel (taxol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Lung Neoplasms (Phase 2)

Neoplasms (Phase 1)

Pancreatic Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 4